Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients

Metabolism: Clinical and Experimental
Ayako IkejiriMitsuru Adachi

Abstract

Dyslipidemia is an important risk factor for cardiovascular disease in patients with chronic renal failure (CRF). We evaluated the safety and efficacy of atorvastatin in patients with dyslipidemia associated with CRF who were undergoing hemodialysis (HD). Thirty-five patients who were receiving HD were given atorvastatin (10 mg/d) for 3 months. Chylomicron (CM), light and dense very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and light and dense low-density lipoprotein (LDL) were separated by ultracentrifugation. Apolipoprotein (apo) B was measured by electroimmunoassay. Mean LDL particle diameter was measured by gradient gel electrophoresis. Atorvastatin therapy reduced LDL-cholesterol (C) by 36% and remnant-like particle (RLP)-C by 58%. Atorvastatin significantly reduced apo B, apo CIII, and apo E in VLDL by 40% to 46% and IDL-apo B by 66%. Atorvastatin also significantly reduced cholesterol in CM, light VLDL, and dense VLDL without consistently affecting triglyceride (TG) in these lipoproteins. Atorvastatin similarly reduced both light and dense LDL-apo B by 38%. LDL particle size in the HD patients significantly increased during atorvastatin treatment from 25.7 +/- 0.4 to 26.2 +/- 0.6 nm. High se...Continue Reading

References

Nov 11, 1992·Biochimica Et Biophysica Acta·L Brissette, L Falstrault
Jun 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·K W MaL Raij
Jan 1, 1986·Methods in Enzymology·A V NicholsT A Musliner
Jan 1, 1983·Methods in Enzymology·J L GoldsteinM S Brown
Dec 31, 1993·Clinica Chimica Acta; International Journal of Clinical Chemistry·K NakajimaE Campos
Jan 1, 1996·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P O AttmanC Knight-Gibson
Sep 18, 1996·JAMA : the Journal of the American Medical Association·M J StampferC H Hennekens
Apr 4, 1998·The American Journal of Cardiology·E A SteinP Laskarzewski
Apr 29, 1998·Journal of Clinical Pharmacology·R H SternS C Olson
Jun 30, 1998·Journal of the American Society of Nephrology : JASN·T ShojiH Morii
Nov 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R N FoleyM J Sarnak
Feb 13, 1999·Kidney International·J ZimmermannC Wanner
Jul 15, 1999·The International Journal of Biochemistry & Cell Biology·T Q TruongL Brissette
May 4, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C J DeighanC J Packard
Jun 30, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·M TamashiroK Fukiyama
Sep 29, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·T ShojiY Nishizawa
Jan 12, 2002·Kidney International·Stephen L SeligerCatherine O Stehman-Breen
Feb 19, 2002·The Annals of Pharmacotherapy·Mohamed A Omar, James P Wilson
Feb 22, 2002·Current Opinion in Nephrology and Hypertension·Domenic A Sica, Todd W B Gehr
Mar 6, 2002·Circulation·Peter LibbyAttilio Maseri
Mar 29, 2002·Kidney International·Kevin P G HarrisUNKNOWN Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis
Jun 19, 2002·Trends in Cardiovascular Medicine·Burkhard LudewigHans Hengartner
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯

Citations

Jun 16, 2006·Cardiovascular Drugs and Therapy·Manfredi Rizzo, Kaspar Berneis
Jun 23, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Sevcan A BakkalogluFirat Kardelen
May 15, 2007·Nephrology·Lisa S JeffsRandall J Faull
May 15, 2007·Kidney International·V M Campese, J Park
Aug 26, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Matthew A RobertsFrancesco L Ierino
Aug 17, 2006·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Tetsuo Shoji, Yoshiki Nishizawa
Mar 17, 2015·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Gustav V B SørensenJeppe H Christensen
Nov 15, 2007·The Annals of Pharmacotherapy·Melanie S JoyCynthia Denu-Ciocca
Dec 24, 2005·QJM : Monthly Journal of the Association of Physicians·M Rizzo, K Berneis
Jun 6, 2015·The International Journal of Artificial Organs·Shelly LichtenbergBenaya Rozen-Zvi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.